4.6 Article

Who Is at Risk for Postdischarge Nausea and Vomiting after Ambulatory Surgery?

期刊

ANESTHESIOLOGY
卷 117, 期 3, 页码 475-486

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/ALN.0b013e318267ef31

关键词

-

资金

  1. Merck & Co., Inc., North Wales, Pennsylvania
  2. MGI Pharma
  3. Eisai (Woodcliff Lake, New Jersey)
  4. Merck Co.
  5. Schering-Plough
  6. Baxter
  7. Helsinn

向作者/读者索取更多资源

Background: About one in four patients suffers from postoperative nausea and vomiting. Fortunately, risk scores have been developed to better manage this outcome in hospitalized paplied to a development dataset and the area under the receiver operating characteristic curve was calculated in a validation dataset. Results: The overall incidence of PDNV was 37%. Logistic regression analysis of the development dataset (n = 1,913) identified five independent predictors (odds ratio; 95% CI): female gender (1.54; 1.22 to 1.94), age less than 50 yr (2.17; 1.75 to 2.69), history of nausea and/or vomiting after previous anesthesia (1.50; 1.19 to 1.88), opioid administration in the postanesthesia care unit (1.93; 1.53 to 2.43), and nausea in the postanesthesia care unit (3.14; 2.44-4.04). In the validation dataset (n = 257), zero, one, two, three, four, and five of these factors were associated with a PDNV incidence of 7%, 20%, 28%, 53%, 60%, and 89%, respectively, and an area under the receiver operating characteristic curve of 0.72 (0.69 to 0.73). Conclusions: PDNV affects a substantial number of patients after ambulatory surgery. We developed and validated a simplified risk score to identify patients who would benefit from long-acting prophylactic antiemetics at discharge from the ambulatory care center.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据